Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

To check cervical cancer, vaccines and information must go together

February 27, 2026 5 min read Social Issues Polity & Governance GS2 GS3
On This Page ▼

What Happened

  • India launched its first nationwide Human Papillomavirus (HPV) vaccination programme on February 28, 2026, targeting approximately 1.15 crore adolescent girls aged 14 years.
  • The vaccination is being rolled out free of charge under the Universal Immunization Programme (UIP) using CERVAVAC, India's indigenously developed HPV vaccine.
  • Within the first two weeks, close to 3 lakh girls received the vaccine, with health officials attributing early uptake to growing community awareness.
  • Health experts emphasize that vaccines alone are insufficient — information campaigns in local languages, NGO partnerships, and community trust-building are critical to reach rural and underserved populations.
  • India accounts for approximately one-fifth of global cervical cancer cases and nearly one-quarter of global deaths from the disease.
  • National cervical cancer screening coverage remains critically low at 1.9% among women aged 30–49, making the vaccine-plus-screening combination essential.

Static Topic Bridges

Universal Immunization Programme (UIP) and Its Expansion

The Universal Immunization Programme (UIP) was launched in 1985 as an expansion of the Expanded Programme on Immunization (EPI, 1978). It is one of the largest public health programmes in the world, targeting approximately 2.67 crore pregnant women and 2.61 crore infants annually. UIP is implemented under the Ministry of Health and Family Welfare and administered through the health system down to the sub-centre level.

  • UIP currently covers vaccines against 12 diseases: tuberculosis, diphtheria, pertussis, tetanus, polio, measles, rubella, hepatitis B, Hib meningitis, pneumococcal pneumonia, rotavirus diarrhoea, and Japanese encephalitis (in endemic areas).
  • Mission Indradhanush (launched 2014) is a sub-program accelerating immunization coverage for under-vaccinated and unvaccinated children.
  • The HPV vaccine's addition to UIP marks the first adolescent vaccine in the national schedule.
  • India's domestically developed HPV vaccine CERVAVAC (by Serum Institute of India) was approved by DCGI in 2022.
  • The National Technical Advisory Group on Immunization (NTAGI) recommended HPV inclusion in UIP for girls aged 9–14 years with a one-time catch-up.

Connection to this news: The national HPV vaccination programme represents a landmark expansion of UIP into adolescent immunization — a shift from the programme's traditional focus on children under five and pregnant women.

Cervical Cancer and HPV: Epidemiology and Prevention Science

Cervical cancer is caused by persistent infection with Human Papillomavirus (HPV), a sexually transmitted virus. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases worldwide. The disease is almost entirely preventable through vaccination (before exposure to the virus) and regular cervical screening (Pap smear or HPV DNA test).

  • India records approximately 1.27 lakh new cervical cancer cases and nearly 80,000 deaths annually (GLOBOCAN 2022).
  • India accounts for ~19% of global cervical cancer incidence and ~23% of global deaths.
  • WHO's 90-70-90 strategy to eliminate cervical cancer as a public health problem requires: 90% of girls fully vaccinated by age 15, 70% of women screened by age 35 and 45, and 90% of women with cervical disease receiving treatment.
  • HPV vaccination is most effective when administered before the onset of sexual activity (ideally ages 9–14).
  • Without intervention, GLOBOCAN projects India's annual cervical cancer cases will rise from 1.27 lakh (2022) to 2.29 lakh by 2050.

Connection to this news: The vaccination programme directly targets the primary prevention leg of cervical cancer control. However, the commentary highlights that the secondary prevention leg — screening at 1.9% coverage — remains severely lagging, underscoring that vaccination alone cannot achieve elimination goals.

Health Communication and Vaccine Hesitancy

Vaccine hesitancy — defined by the WHO's Strategic Advisory Group of Experts (SAGE) as the "delay in acceptance or refusal of vaccines despite availability of vaccine services" — is recognized as one of the ten greatest threats to global health. For HPV vaccines specifically, hesitancy is driven by misconceptions about the vaccine promoting sexual activity, concerns about side effects, and insufficient awareness of the HPV-cervical cancer link.

  • India's ASHA (Accredited Social Health Activist) network, comprising over 10 lakh workers, is the primary frontline vehicle for health communication at the community level.
  • The Right to Health is recognized as part of Article 21 (right to life) by the Supreme Court, creating a justiciable duty on the state to ensure access to healthcare.
  • National Health Policy 2017 targets Universal Health Coverage and emphasizes preventive and promotive health alongside curative care.
  • The National Health Mission (NHM), launched in 2013 combining NRHM (2005) and NUHM (2013), provides the administrative and financial backbone for immunization outreach.
  • Information, Education, and Communication (IEC) activities are a dedicated component of NHM budgets.

Connection to this news: The gap between vaccine availability and actual uptake highlighted in this article directly maps to the health communication challenge — the vaccine has been approved and rolled out, but the information ecosystem surrounding it, particularly in rural areas, remains underdeveloped.

India's Pharmaceutical Sovereignty — CERVAVAC

CERVAVAC is the first indigenously developed quadrivalent HPV vaccine, manufactured by the Serum Institute of India (SII), Pune. Its development was partly supported by grants from the Bill & Melinda Gates Foundation and the Department of Biotechnology (DBT). It received approval from India's Drugs Controller General of India (DCGI) in January 2022 after successful phase II/III clinical trials in India.

  • CERVAVAC offers protection against HPV types 6, 11, 16, and 18.
  • At approximately ₹200 per dose (public sector pricing), it is significantly cheaper than imported HPV vaccines (Gardasil, Cervarix) which cost ₹2,000–4,000 per dose in the private market.
  • India has a constitutional mandate under Article 47 to raise the level of nutrition and standard of living and improve public health.
  • The Department of Biotechnology under DST is responsible for supporting vaccine R&D; National Biopharma Mission (2017) is the umbrella program.
  • SII's CERVAVAC can also be exported to low-income countries under GAVI's vaccine procurement programme.

Connection to this news: CERVAVAC's cost-effectiveness makes it feasible to include in UIP at scale. This represents a direct application of India's "Atmanirbhar Bharat" (self-reliance) principle in healthcare, reducing dependence on costly imported vaccines for a disease that disproportionately burdens India's poorest women.

Key Facts & Data

  • Target cohort for 2026 vaccination drive: ~1.15 crore girls aged 14 years.
  • GLOBOCAN 2022: India — 1,27,526 new cervical cancer cases, 79,906 deaths annually.
  • India's cervical cancer screening coverage: 1.9% (among women aged 30–49).
  • Global benchmark under WHO 90-70-90 strategy: 90% vaccination, 70% screening by age 35 and 45, 90% treatment.
  • CERVAVAC approved by DCGI: January 2022.
  • HPV vaccination schedule: two doses for 9–14 year olds (0 and 6 months); three doses for 15+ year olds.
  • First two weeks of programme (after Feb 28, 2026): approximately 3 lakh girls vaccinated.